TrialBritish journal of cancer2015

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.

A P Algazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.